1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: A post-AdCom assessment of Novo Nordisk's liraglutide for obesity

Physician Views: A post-AdCom assessment of Novo Nordisk's liraglutide for obesity

  • September 2014
  • ID: 2387286
  • Format: PDF
  • Firstword Pharma

Summary






Novo Nordisk took an important step in its bid to enter the obesity market last week, when an FDA Advisory Committee voted 14-1 in favour to approve a 3mg version of its diabetes treatment liraglutide for this indication.

This outcome reflects validation of the efficacy profile demonstrated by liraglutide in obesity, noted analysts, but importantly also showed that there was minimal concern about its side-effect profile. Indeed, analysts at JP Morgan described the FDA presentation as 'benign,' and stated that there is an increased likelihood that approval will occur on or before October 20.

A few side-effect concerns linger, but post-AdCom consensus suggests these will act to shape how the product is utilised by physicians, rather than dictate whether it gains approval. The commercial opportunity for liraglutide – which will be sold under the brand name Saxenda – is one that is still open to some debate. For example, beyond the clinical profile of liraglutide as an obesity therapy, will uptake be limited due to the drug's cost and injectable administration, argue bearish analysts.

Novo Nordisk hopes that Saxenda proves to be predictive of a longer-term success in the obesity market, which will centre around the development of new therapies designed to target the underlying mechanics of the condition – see Spotlight On: Exit from inflammatory development a case of time management, explains Novo Nordisk's chief science officer to FirstWord.

The commercial opportunity for Saxenda may hang on a more straightforward rationale, however, and depend on how many existing diabetes patients treated with liraglutide 1.8mg (as Victoza) who are also morbidly obese can be 'up-scaled' with treatment to the 3mg version – which could sell for around 3 times the price of Victoza based on a consensus of analyst estimates (and taking into account comments about pricing from Novo management).

Reflecting a key component of Novo Nordisk's obesity strategy – which is to target physicians they are familiar with and whom are familiar with the company's products – severely obese pre-diabetic patients and those suffering with obesity and other co-morbidities will initially be targeted to use Saxenda.








With these factors in mind – and given last week's positive AdCom vote – FirstWord is polling US-based endocrinologists and general practitioners on their anticipated usage of Saxenda, assuming that approval is secured. Specifically we are asking them...


To what percentage of obese diabetics (BMI>40) – already receiving treatment with a GLP-1 agonist – they would expect to prescribe the higher 3mg dose of liraglutide if approved for obesity
Whether approval of liraglutide 3mg for obesity would encourage them to switch more diabetics (not being treated with a GLP-1 agonist) to treatment with Victoza (on account of approval further validating liraglutide's weight-loss profile)
To what percentage of morbidly obese patients with pre-diabetes they would anticipate prescribing 3mg liraglutide
To what percentage of morbidly obese patients with other co-morbidities they would anticipate prescribing 3mg liraglutide
What factors will act as significant barriers to their potential usage of 3mg liraglutide for the treatment of obesity



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

GLP-1 Receptor Agonist Market Forecast, Trend Analysis & Opportunity Assessment 2020-2030

  • $ 5000
  • August 2020
  • 280 pages

GLP-1 Receptor Agonist Market: Global Industry Analysis 2015-2019 & Opportunity Assessment 2020-2030 A recent market study published on the GLP-1 Receptor Agonist Market offers global industry analysis ...

  • World
  • South Asia
  • Glucagon Like Peptide 1 Receptor Activator
  • Infectious Disease
  • Industry analysis

ref:plp2014

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on